Compare BigBearai Holdings Inc (BBAI) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BigBearai Holdings Inc vs Bristol-Myers Squibb Co — how do they compare? BigBearai Holdings Inc trades at $3.25 (market cap $1.60B), while Bristol-Myers Squibb Co trades at $63.53 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is far larger — about 81.2× BigBearai Holdings Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while BigBearai Holdings Inc pays none. Which is the better fit depends on your goals.
| BBAI | BMY | |
|---|---|---|
Market Cap | $1.60B | $129.94B |
Sector | Technology | Health |
52-Week High | $8.91 | $65.89 |
52-Week Low | $2.61 | $42.60 |
Enterprise Value | $1.30B | $163.92B |
Dividend Yield | — | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BigBear.ai (BBAI) trades at $3.32, up 2.79% with a bullish technical signal. The company reported Q2 2026 revenue growth of 13% but missed EPS expectations. Despite negative profitability metrics (-65.2% net margin), the stock shows institutional interest with 75% analyst hold ratings. Recent news highlights defense contract wins and generative AI platform expansion for Department of War missions.
Outlook remains cautious due to persistent losses and revenue headwinds, though backlog growth and government contracts provide stability. Investment opportunity exists in AI defense specialization, but risks include execution challenges and competitive pressure. The stock requires careful monitoring of profitability improvements and contract execution.
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BigBearai Holdings Inc
BigBearai Holdings Inc is a specialized provider of AI-driven decision intelligence solutions, primarily serving the U.S. defense, intelligence, and national security communities. It operationalizes complex data into actionable insights through its core modules—Observe, Orient, and Dominate—to support mission-critical operations and logistics.
Read more on BBAI →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
